Maia Biotechnology Inc (MAIA)

$MAIA in addition to what Chemaster said, the new molecules are well-suited for hemooncology. MAIA is gonna eats GERN alive 🥂

$MAIA @Chemaster Have you actually looked at the 'next gen' THIO? It looks like just a dimer to me - yawn! Why not read the article and post the structures so people can compare ? 6-10 uM in culture is a double yawner - we have had things in the nanomolar range (1000X more potent) that didn't get further developed

$MAIA @Jack37615 IMO, Too bad your attempt at a compelling post leaves out important details and history of shenanigans. IMO a rug pull is 10X more likely than these repeated outrageous buyout speculations of SLS.

$MAIA cantor said, tariffs were legal His word is siht

$MAIA GREAT INFO: The new thing is not really THIO itself. It is MAIA's second-generation drugs built from the THIO concept. Telomerase, your take is the following accurate? This is your expertise. The standout is MAIA-2022-12. They tested it against THIO across 77 cancer cell lines, and its average EC50 was 6.64 μM versus 8.72 μM for THIO—lower is better—and that difference was statistically significant. It also showed strong tumor inhibition in mouse models and evidence of immune memory. So the interesting message is: MAIA may have something beyond THIO. THIO is the drug already in human development, while MAIA-2022-12 and MAIA-2021-20 are next-generation molecules intended to improve on the same telomere-targeting idea. MAIA currently identifies MAIA-2021-20 as the lead and MAIA-2022-12 as the backup candidate for further preclinical development.

$MAIA MAIA presentation at IRT 2026: https://maiabiotech.com/wp-content/uploads/2026/08/maia_irt_2026_poster.pdf

$MAIA I got to thinkin and I can so see Eli Lilly droptin 10 B once interim hits if not before. Because they have It like that.

$MAIA I never cross post at all, but the moment an $SLS buyout takes place (as I’ve told myself I won’t be selling a single share up until that point), a significant portion of my post-tax earnings will be unwinded into MAIA. I see the company as as an earlier stage SLS with growing legs that carry many similarities. I’m not here to pump anything as I do not have a sizeable position in MAIA for the time being, but for those who are looking for a company to invest in other than/after SLS, here are a few similarities to note for those who seek interest Both are OS based, randomized 1:1, open label P3 studies Both have shown efficacy signals that outperform control therapies relative to historical outcomes by multiples in P2 (largest factor) Both dosing regimens are conceptually similar (relative to GPS’s ad infintrum dosing) Both have strong, encouraging safety profiles Both drugs have a platform-like potential to expand across multiple cancer types Both are granted FDA fast track designation Both have rationale for combination with checkpoint inhibitors Both are attacking multi-billion dollar markets Both Phase 3 OS studies are ≥90% powered relative to their respective control therapies - THIO is designed with 90% power to detect an HR of .62, while REGAL has been described as ≥90% powered under an assumed HR of .52, with ~.636 representing stat sig GPS and Ateganosine work through different initial mechanisms but converge on a similar immune mediated process which is what got me so interested. As many in SLS know, GPS presents WT1 derived peptides to the immune system, stimulating WT1 specific CD4+ and CD8+ T cells that recognize and kill WT1 expressing cancer cells, whereas THIO is incorporated into the telomeres of telomerase positive cancer cells, causing telomere damage and cancer cell stress/death that activates pathways such as cGAS-STING, promotes antigen presentation, and ultimately recruits tumor-specific cytotoxic T cells. In short, GPS directly trains adaptive immunity against a defined tumor antigen, while THIO creates tumor damage that helps provoke adaptive antitumor immunity. Both aim to generate T-cell mediated recognition and destruction of cancer cells with durable immune memory, which is what I love about the two drugs. My assumption on an assumed interim data analysis for THIO is anytime after summer of 2027, so it gives a nice gap of time between the two companies to ponder more on the science and data of MAIA. The design explicitly states 90% power to detect HR = 0.62, based on 9.4 months OS versus 5.8 months for chemotherapy, with FA at 186 deaths. Whats great for the mOS of this drug is the P2 efficacy showed 17.8 months in 22 third-line patients, 95% CI lower bound was 12.5 months and the 99% CI lower bound was 10.8 months relative to the published chemotherapy outcomes of roughly 5–6 months OS in similar later-line NSCLC populations. The P2 efficacy relative to control therapies + P3 trial design is what gets me locked onto the company. This is similar to separate components of SLS’s company, giving lots of confidence that I’m investing in a mechanism that’s soon to be strongly proven. A boat load of shares will be docked into this company when the time comes that SLS is off the market. GLTA.

$MAIA Just listened to the GERN call with Cantor. They were talking smaller acquisitions… wonder if they would ever try to acquire MAIA?

$MAIA Just be aware of these pre-market and post-market spreads and how at times they are manipulated to discourage retail Bulls and get your shares at open at discounts. For example, and just this morning. Bid: 1.33 x 800 Ask: 1.40 x 1100 Last trade 1.33 Price shown here and at broker I've seen very low volume trades come in almost every situation on the low side. Many traders use this spread to set the opening price which in this case is .07 cents below the ask. .07 cents doesn't seem like much but if you have 10k shares is $700 and 100k shares is $7,000 or many here $14,000. It's been know for years that some traders will buy / sell a low volumn (ie 50) shares and will buy 50 shares at 1.40 and immediately sell the same at 1.33 just to get the last trade. Its looks like you are down $7000 near open and will either feel discouraged or place a sale based on the value they see at low prices. If they see a pre-market price at 1.33, some would put in a day limit sale at 1.34 or 1.35. I'm sure most traders understand this without me saying so. However, if you are new to trading just be aware of high gap effects during pre - post market. NFA